Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qurse Revand in MASLD
NCT07902219Phase 2Not yet recruiting
- Sponsor
- National Institute of Unani Medicine
- Start
- May 2027
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by National Institute of Unani Medicine. Primary endpoint: Change in Fatty Liver Grading by USG at 60 days. Planned start May 2027; status: not yet recruiting.
02
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT07902219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07902219.